ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

liposomal doxorubicin

Also written as “PLD”, “Doxorubicin Hydrochloride Liposome Injection” and “Pegylated liposomal doxorubicin”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Multiple Myeloma · Carcinoma, Ovarian Epithelial · Endometrial Neoplasms, led by 16 companies.

Drug pageLiposomal doxorubicin: every studyMany companies study it; this page follows only the 33 they lead. All 210 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 29, 200433 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only90 open or runningphase 3since Apr 29, 2004Apr 29, 2004none ahead
Merckits history only60 open or runningphase 4since Jan 21, 2008Dec 15, 2005none ahead
CSPC Pharmaceutical Groupits history only20 open or runningphase 2since Dec 11, 2017Dec 11, 2017none ahead
Imunonits history only20 open or runningphase 2since Nov 1, 2011Jun 5, 2003none ahead
Oncotherapeuticsits history only20 open or runningphase 2since Aug 26, 2008Aug 26, 2008none ahead
TTY Biopharmits history only20 open or runningphase 2since Aug 31, 2010Aug 31, 2010none ahead
Ayana Pharmaits history only10 open or runningphase 1since Sep 17, 2018Sep 17, 2018none ahead
Azaya Therapeuticsits history only10 open or runningphase 1since Oct 19, 2012Oct 19, 2012none ahead
Baxter Healthcareits history only10 open or runningphase 1since Sep 29, 2022Sep 29, 2022none ahead
Dr. Reddy's Laboratories10 open or runningphase 1since Sep 22, 2014Sep 22, 2014none ahead

Also a collaborator on its studies: Eisai, Novotech (Australia) Pty, Lambda Therapeutic Research, MDS Pharma Services, Essex Pharma, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA, Ortho Biotech, Tibotec Pharmaceutical, Sequus Pharmaceuticals and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr. Reddy's Laboratories only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2014First study: phase 1 study in Ovarian Epithelial Cancer RecurrentFirst studyNCT02260544 · 49 enrolled · India

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Dr. Reddy's Laboratories leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02260544Ovarian Epithelial Cancer Recurrent · India1CompletedApr 201549

How it is read

Names in the registry

  • “PLD”, 4 entries
  • “Doxorubicin Hydrochloride Liposome Injection”, 4 entries
  • “Pegylated liposomal doxorubicin”, 3 entries
  • “Pegylated Liposomal Doxorubicin (PLD)”, 2 entries
  • “liposomal doxorubicin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.